Phase II study of Nab-paclitaxel followed by FEC as neoadjuvant chemotherapy for the operable breast cancer
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2019
Price : $35 *
At a glance
- Drugs Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 04 Feb 2019 Status changed from active, no longer recruiting to discontinued.
- 27 Sep 2015 Status changed from recruiting to active, no longer recruiting as per results presented at the ASCO - Breast Cancer Symposium 2015 .
- 27 Sep 2015 Results presented at the ASCO - Breast Cancer Symposium 2015